Addex Therapeutics Capital Expenditures (CapEx) Growth & History (ADXN)
Addex Therapeutics's capital expenditures (capex) was CHF1,273 for fiscal 2024.
View full Addex Therapeutics company overviewAddex Therapeutics annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2024 | 2024-12-31 | CHF1,273 | −CHF5,569 | −81.39% |
| 2023 | 2023-12-31 | CHF6,842 | CHF6,261 | +1077.62% |
| 2022 | 2022-12-31 | CHF581 | −CHF30,968 | −98.16% |
| 2021 | 2021-12-31 | CHF31,549 | −CHF27,865 | −46.90% |
| 2020 | 2020-12-31 | CHF59,414 | CHF30,955 | +108.77% |
| 2019 | 2019-12-31 | CHF28,459 | CHF19,405 | +214.33% |
| 2018 | 2018-12-31 | CHF9,054 | CHF8,357 | +1199.00% |
| 2017 | 2017-12-31 | CHF697 | — | — |
Addex Therapeutics quarterly capital expenditures (capex)
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2025 | 2025-06-30 | CHF0 | CHF0 | — |
| Q2 2024 | 2024-06-30 | CHF0 | — | — |
Addex Therapeutics capital expenditures (capex) trends
Over the last five fiscal years, Addex Therapeutics's capital expenditures (capex) decreased from CHF28,459 to CHF1,273, a change of −CHF27,186. The latest reported quarter, Q2 2025, shows CHF0.
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Addex Therapeutics source filings ↗